Recruiting
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease - RPC01-3204
Updated: 15 September, 2023 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com Inclusion Criteria: - Is not in clinical response or clinical remission after completing 12 weeks in the Induction Studies - Experience relapse or who complete the Maintenance Study - Complete a study of ozanimod for Crohn's Disease and meet the criteria for participation Exclusion Criteria: - Has any clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine, psychiatric, or other major systemic disease making implementation of the protocol or interpretation of the study difficult or that would put the subject at risk by participating in the study - Has suspected or diagnosed intra-abdominal or perianal abscess that has not been appropriately treated - Is receiving treatment with any of the following drugs or interventions: CYP2C8 inducers; Monoamine oxidase inhibitors Other protocol-defined inclusion/exclusion criteria apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
